tbuckley/cabot-search huggingface dataset:
A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice
Authors: Tian-Ying Zhang, Xue-Ran Guo, Yang-Tao Wu, Xiao-Zhen Kang, Qing-Bing Zheng, Ruo-Yao Qi, Bin-Bing Chen, Ying Lan, Min Wei, Shao-Juan Wang, Hua-Long Xiong, Jia-Li Cao, Bao-Hui Zhang, Xiao-Yang Qiao, Xiao-Fen Huang, Ying-Bin Wang, Mu-Jin Fang, Ya-Li Zhang, Tong Cheng, Yi-Xin Chen, Qin-Jian Zhao, Shao-Wei Li, Sheng-Xiang Ge, Pei-Jer Chen, Jun Zhang, Quan Yuan, Ning-shao Xia
Journal: Gut (2019)

Objective This study aimed to develop a novel therapeutic vaccine based on a unique B cell epitope and investigate its therapeutic potential against chronic hepatitis B (CHB) in animal models. Methods A series of peptides and carrier proteins were evaluated in HBV-tolerant mice to obtain an optimised therapeutic molecule. The immunogenicity, therapeutic efficacy and mechanism of the candidate were investigated systematically. Results Among the HBsAg-aa119-125-containing peptides evaluated in this study, HBsAg-aa113-135 (SEQ13) exhibited the most striking therapeutic effects. A novel immunoenhanced virus-like particle carrier (CR-T3) derived from the roundleaf bat HBV core antigen (RBHBcAg) was created and used to display SEQ13, forming candidate molecule CR-T3-SEQ13. Multiple copies of SEQ13 displayed on the surface of this particulate antigen promote the induction of a potent anti-HBs antibody response in mice, rabbits and cynomolgus monkeys. Sera and purified polyclonal IgG from the immunised animals neutralised HBV infection in vitro and mediated efficient HBV/hepatitis B virus surface antigen (HBsAg) clearance in the mice. CR-T3-SEQ13-based vaccination induced long-term suppression of HBsAg and HBV DNA in HBV transgenic mice and eradicated the virus completely in hydrodynamic-based HBV carrier mice. The suppressive effects on HBsAg were strongly correlated with the anti-HBs level after vaccination, suggesting that the main mechanism of CR-T3-SEQ13 vaccination therapy was the induction of a SEQ13-specific antibody response that mediated HBV/HBsAg clearance. Conclusions The novel particulate protein CR-T3-SEQ13 suppressed HBsAg effectively through induction of a humoural immune response in HBV-tolerant mice. This B cell epitope-based therapeutic vaccine may provide a novel immunotherapeutic agent against chronic HBV infection in humans.
Cancer-testis antigens in triple-negative and locally advanced breast cancer.
Authors: Samuel John Harris, Natalie Heather Turner, Fiona J.M. Chionh, Marzena Walkiewicz, Anannya Chakrabarti, Siddhartha Deb, Jonathan S. Cebon, Shane White, Tom John
Journal: Journal of Clinical Oncology (2013)

11072 Background: Cancer-Testis Antigens (CTAs) are immunogenic molecules that have increased expression in triple negative breast cancers (TNBC), a phenotype that whilst associated with poorer survival, is chemosensitive. We investigated expression of the CTAs MAGE-A, MAGE-C1, and NY-ESO-1 in women with Locally Advanced Breast Cancers (LABC) and TNBC to determine the association between CTA expression, survival and response to chemotherapy. Methods: We reviewed patient charts, treated for either TNBC or LABC between 1997 and 2011. Tissue samples were used for immunohistochemical (IHC) staining for MAGE-A, MAGE-C1 and NY-ESO-1 and compared using Fisher’s exact test. Positive expression was defined as any antigen staining above background.. Clinicopathological features were correlated with IHC results and survival estimated using the Kaplan Meier method. Results: A total of 106 cases were investigated (64 TNBC and 42 LABC). In the TNBC cohort the median age was 58 and TNM stages 1 to 3c. CTA expression occurred in 56, 51 and 43% for MAGE-A, MAGE-C1 and NY-ESO-1 respectively. CTA expression was not associated with overall survival (OS) or time to progression. In the LABC cohort the median age was 54 and consisted of stage IIIb tumors. All breast cancer subtypes were represented. CTA expression occurred in 26, 64 and 21% for MAGE-A, MAGE-C1 and NY-ESO-1 respectively. There was no association between CTA expression and response to chemotherapy. In a univariate analysis MAGE-A expression in the LABC group was associated with poorer OS (median 25 vs 76 months, HR 3.347 95% CI 1.44 to 21.68, p=0.015). However, there were more TN patients and Grade 3 tumors in the MAGE-A positive group. Across the two groups, MAGE-A (51 vs 14% p=0.002) and NY-ESO-1 (37 vs 2% p=0.006) but not MAGE-C1 had significantly higher expression in ER -ve tumors. There was higher expression of MAGE-A (51 vs 25% p=0.025) and NY-ESO-1 (43 vs 10% p=0.002) in Grade 3 tumors. Conclusions: MAGE-A, MAGE-C1 and NY-ESO-1 are highly expressed in TNBC and high-grade subsets of early breast cancer. CTA expression in TNBC was not predictive of survival nor response to chemotherapy in LABC. However, MAGE-A expression was found to be associated with poorer overall survival in LABC.
Efficacy of ALL Therapy for WHO2016-Defined Mixed Phenotype Acute Leukemia: A Report from the Children's Oncology Group
Authors: Etan Orgel, Thomas B. Alexander, Brent Wood, Samir Kahwash, Meenakshi Devidas, Yunfeng Dai, Todd A Alonzo, Charles G. Mullighan, Hiroto Inaba, Stephen P. Hunger, Alan S Gamis, Andrew J. Carroll, Nyla A. Heerema, Jason Berman, William G Woods, Mignon L. Loh, Patrick A. Zweidler-McKay, John T Horan
Journal: Blood (2017)
Older People Might Be at Most Serious Risk in Antihypertensive Treatment
Authors: Fatih Tufan
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Aire-expressing ILC3-like cells in the lymph node display potent APC features
Authors: Tomoyoshi Yamano, Jan Dobeš, Matouš Vobořil, Madlen Steinert, Tomáš Brabec, Natalia Ziętara, Martina Dobešová, Caspar Ohnmacht, Martti Laan, Part Peterson, Vladimir Benes, Radislav Sedláček, Rikinari Hanayama, Michal Kolář, Ludger Klein, Dominik Filipp
Journal: The Journal of Experimental Medicine (2019)

The autoimmune regulator (Aire) serves an essential function for T cell tolerance by promoting the "promiscuous" expression of tissue antigens in thymic epithelial cells. Aire is also detected in rare cells in peripheral lymphoid organs, but the identity of these cells is poorly understood. Here, we report that Aire protein-expressing cells in lymph nodes exhibit typical group 3 innate lymphoid cell (ILC3) characteristics such as lymphoid morphology, absence of "classical" hematopoietic lineage markers, and dependence on RORγt. Aire+ cells are more frequent among lineage-negative RORγt+ cells of peripheral lymph nodes as compared with mucosa-draining lymph nodes, display a unique Aire-dependent transcriptional signature, express high surface levels of MHCII and costimulatory molecules, and efficiently present an endogenously expressed model antigen to CD4+ T cells. These findings define a novel type of ILC3-like cells with potent APC features, suggesting that these cells serve a function in the control of T cell responses.
Enhanced Neurite Outgrowth on a Multiblock Conductive Nerve Scaffold with Self‐Powered Electrical Stimulation
Authors: Yi Sun, Qi Quan, Haoye Meng, Yudong Zheng, Jiang Peng, Yaxin Hu, Zhaoxuan Feng, Xiao Sang, Kun Qiao, Wei He, Xiaoqi Chi, Liang Zhao
Journal: Advanced Healthcare Materials (2019)

Electrical stimulation (ES) is widely applied to promote nerve regeneration. Currently, metal needles are used to exert external ES, which may cause pain and risk of infection. In this work, a multiblock conductive nerve scaffold with self-powered ES by the consumption of glucose and oxygen is prepared. The conductive substrate is prepared by in situ polymerization of polypyrrole (PPy) on the nanofibers of bacterial cellulose (BC). Platinum nanoparticles are electrodeposited on the anode side for glucose oxidation, while nitrogen-doped carbon nanotubes (N-CNTs) are loaded on the cathode side for oxygen reduction. The scaffold shows good mechanical property, flexibility and conductivity. The scaffold can form a potential difference of above 300 mV between the anode and the cathode in PBS with 5 × 10-3 m glucose. Dorsal root ganglions cultured on the Pt-BC/PPy-N-CNTs scaffold are 55% longer in mean neurite length than those cultured on BC/PPy. In addition, in vivo study indicates that the Pt-BC/PPy-N-CNTs scaffold promotes nerve regeneration compared with the BC/PPy group. This paper presents a novel design of a nerve scaffold with self-powered ES. In the future, it can be combined with other features to promote nerve regeneration.
Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non–Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial
Authors: Andrea Bezjak, Rebecca Paulus, Laurie E. Gaspar, Robert D. Timmerman, William L. Straube, William F. Ryan, Yolanda I. Garces, Anthony T. Pu, Anurag K. Singh, Gregory M. Videtic, Ronald C. McGarry, Puneeth Iyengar, Jason R. Pantarotto, James J. Urbanic, Alexander Y. Sun, Megan E. Daly, Inga S. Grills, Paul Sperduto, Daniel P. Normolle, Jeffrey D. Bradley, Hak Choy
Journal: Journal of Clinical Oncology (2019)

PURPOSE Patients with centrally located early-stage non–small-cell lung cancer (NSCLC) are at a higher risk of toxicity from high-dose ablative radiotherapy. NRG Oncology/RTOG 0813 was a phase I/II study designed to determine the maximum tolerated dose (MTD), efficacy, and toxicity of stereotactic body radiotherapy (SBRT) for centrally located NSCLC. MATERIALS AND METHODS Medically inoperable patients with biopsy-proven, positron emission tomography–staged T1 to 2 (≤ 5 cm) N0M0 centrally located NSCLC were accrued into a dose-escalating, five-fraction SBRT schedule that ranged from 10 to 12 Gy/fraction (fx) delivered over 1.5 to 2 weeks. Dose-limiting toxicity (DLT) was defined as any treatment-related grade 3 or worse predefined toxicity that occurred within the first year. MTD was defined as the SBRT dose at which the probability of DLT was closest to 20% without exceeding it. RESULTS One hundred twenty patients were accrued between February 2009 and September 2013. Patients were elderly, there were slightly more females, and the majority had a performance status of 0 to 1. Most cancers were T1 (65%) and squamous cell (45%). Organs closest to planning target volume/most at risk were the main bronchus and large vessels. Median follow-up was 37.9 months. Five patients experienced DLTs; MTD was 12.0 Gy/fx, which had a probability of a DLT of 7.2% (95% CI, 2.8% to 14.5%). Two-year rates for the 71 evaluable patients in the 11.5 and 12.0 Gy/fx cohorts were local control, 89.4% (90% CI, 81.6% to 97.4%) and 87.9% (90% CI, 78.8% to 97.0%); overall survival, 67.9% (95% CI, 50.4% to 80.3%) and 72.7% (95% CI, 54.1% to 84.8%); and progression-free survival, 52.2% (95% CI, 35.3% to 66.6%) and 54.5% (95% CI, 36.3% to 69.6%), respectively. CONCLUSION The MTD for this study was 12.0 Gy/fx; it was associated with 7.2% DLTs and high rates of tumor control. Outcomes in this medically inoperable group of mostly elderly patients with comorbidities were comparable with that of patients with peripheral early-stage tumors.
AB0192 Influence of exercise on bone mineral density
Authors: SC Brankovic, NZ Pilipovic, P Vukojevic
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Parameters of the ideal exercise programs, such as type, frequency, intensity and duration of activity are unknown. When women with sedentary way of life (&lt; 30 min of exercise per week) began a strenuous training program, bone mass increased significantly. Regular physical activity may help to maintain skeletal integrity throughout life and possibly reduce the long-term risk for fracture. Exercise intervention may provide modest increases in bone mass, but after one year period of detraining, BMD had returned to baseline, indicating that exercise must be sustained for bone mineral improvements to persist. <h3>Objectives</h3> The aim of study was to assess the effects of our exercise program on bone mineral density in the prevention and treatment of osteoporosis. <h3>Methods</h3> We developed a exercise program in Institute of Rheumatology and the patients with low bone mineral density (BMD) exercised 3 times a week (for 4 weeks). After that period patients continued regularly with exercise at home. BMD was measured by dual x-ray absorptiometry (Lunar DXA system). <h3>Results</h3> Group of 24 pts who only exercised without taking any drugs for osteoporosis, mean age 57,38 (46–73) years and mean BMD 0,915 ± 0,12 gr/cm<sup>2</sup> with average T score -2,40 ± 0,98. The control DXA was done after average period of 10, 3 months. BMD was increased to mean 0,925 ± 0,10 gr/cm<sup>2</sup> (1,5%), and T score to -2,28 ± 0,88 (3,7%), (N. S.) Sixteen patients with BMD 9,23 ± 0,07 gr/cm<sup>2</sup> did not continued with exercising, and after average 11,7 months BMD was decreased to 9,04 ± 0,06 gr/cm<sup>2</sup> (2,1%);(t = 2,21; p &lt; 0,05) <h3>Conclusion</h3> Our result suggests that exercise have a positive effect on BMD even without medical therapy. It is necessary to continue with exercise at home because BMD decreased more than returned to baseline.
Michael's Testimonial
Authors: Roger S. LaBonte
Journal: Annals of Internal Medicine (2019)

Letters2 April 2019Michael's TestimonialRoger S. LaBonte, MDRoger S. LaBonte, MDUniversity of Tennessee Health Science Center, Memphis, Tennessee (R.S.L.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L19-0043 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:After reading Danielson and Dubé's essay (1), I reviewed recent legal arguments about California's End of Life Option Act. This legislation was first approved in 2015 and put into effect in 2016. According to Superior Court Judge Daniel A. Ottolia, who overturned the act, the California legislature violated the law by passing it during a special session dedicated to health care issues (2).We should heed Danielson and Dubé's eloquent and logical argument that Danielson and others like him have a right to die with dignity when faced with a devastating terminal illness. He obviously has approached ...References1. Danielson MM, Dubé K. Michael's testimonial. Ann Intern Med. 2018;169:349. [PMID: 30178018]. doi:10.7326/M18-1719 LinkGoogle Scholar2. Karlamanga S. Riverside judge overturns California's doctor-assisted suicide law. Los Angeles Times. 15 May 2018. Accessed at www.latimes.com/local/lanow/la-me-ln-end-of-life-option-act-20180515-story.html on 12 December 2018. Google Scholar3. Meier DE, Emmons CA, Wallenstein S, Quill T, Morrison RS, Cassel CK. A national survey of physician-assisted suicide and euthanasia in the United States. N Engl J Med. 1998;338:1193-201. [PMID: 9554861] CrossrefMedlineGoogle Scholar4. Bermudez E. California appeals court reinstates law allowing terminally ill patients to end their lives. Los Angeles Times. 15 June 2018. Accessed at www.latimes.com/local/california/la-me-ln-suicide-law-20180615-story.html on 12 December 2018. Google Scholar Author, Article, and Disclosure InformationAffiliations: University of Tennessee Health Science Center, Memphis, Tennessee (R.S.L.)Disclosures: The author has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L19-0043. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoMichael's Testimonial Michael M. Danielson and Karine Dubé Michael's Testimonial Stephen Strum Michael's Testimonial David Killoran Michael's Testimonial Michael M. Danielson and Karine Dubé Metrics 2 April 2019Volume 170, Issue 7Page: 510KeywordsAmyotrophic lateral sclerosisConflicts of interestDisclosureHealth careLegislationSuicide ePublished: 2 April 2019 Issue Published: 2 April 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Results Of The Large Prospective Study On The Use Of Defibrotide (DF) In The Treatment Of Hepatic Veno-Occlusive Disease (VOD) In Hematopoietic Stem Cell Transplant (HSCT). Early Intervention Improves Outcome - Updated Results Of a Treatment IND (T-IND) Expanded Access Protocol
Authors: Paul G. Richardson, Angela R. Smith, Brandon M. Triplett, Nancy A. Kernan, Stephan A Grupp, Sally Arai, Paul R. Haut, Paul L. Martin, Heather J. Symons, Leslie E. Lehmann, Tiffany Simms-Waldrip, Alfred P. Gillio, Biljana N. Horn, Tsiporah B. Shore, Amrita Y. Krishnan, Aleksandra Petrovic, Ivan I. Kirov, Ann E. Woolfrey, Robert J. Greiner, Shin Mineishi, Michael Boyer, Alison L. Hannah, Joseph H. Antin, Robin Hume, Valeria Bandiera, Carin Heringa, Robert J. Soiffer
Journal: Blood (2013)
Lymphatic impairment leads to pulmonary tertiary lymphoid organ formation and alveolar damage
Authors: Hasina Outtz Reed, Liqing Wang, Jarrod Sonett, Mei Chen, Jisheng Yang, Larry Li, Petra Aradi, Zoltan Jakus, Jeanine D’Armiento, Wayne W. Hancock, Mark L. Kahn
Journal: Journal of Clinical Investigation (2019)

The lung is a specialized barrier organ that must tightly regulate interstitial fluid clearance and prevent infection in order to maintain effective gas exchange. Lymphatic vessels are important for these functions in other organs, but their roles in the lung have not been fully defined. In the present study, we addressed how the lymphatic vasculature participates in lung homeostasis. Studies using mice carrying a lymphatic reporter allele revealeded that, in contrast to other organs, lung lymphatic collecting vessels lack smooth muscle cells entirely, suggesting that forward lymph flow is highly dependent on movement and changes in pressure associated with respiration. Functional studies using CLEC2-deficient mice in which lymph flow is impaired due to loss of lympho-venous hemostasis or using inducible lung-specific ablation of lymphatic endothelial cells in a lung transplant model revealeded that loss of lymphatic function leads to an inflammatory state characterized by the formation of tertiary lymphoid organs (TLOs). In addition, impaired lymphatic flow in mice resulteds in hypoxia and features of lung injury that resemble emphysema. These findings reveal both a lung-specific mechanism of lymphatic physiology and a lung-specific consequence of lymphatic dysfunction that may contribute to chronic lung diseases that arise in association with TLO formation.
Abstract IA04: Targeting the expression of EWS-FLI1
Authors: Nirmalya Sen, Katelyn Ludwig, Guillermo O. Rangel-Rivera, Suntae Kim, Konrad Huppi, Lisa Jenkins, Jennifer E. Dwyer, Shelley Hoover, Lee Helman, Mark Simpson, Arnulfo Mendoza, Amanda B. Hummon, Natasha J. Caplen
Journal: Clinical Cancer Research (2018)

Abstract Post-translational modifications (PTMs) of transcription factors represent potential therapeutic targets for a variety of diseases, including cancer. In the majority of cases of the bone and soft tissue tumor Ewing sarcoma (ES), a chromosomal translocation, t(11:22), results in expression of the fusion transcription factor EWS-FLI1. Few PTMs of EWS-FLI1 have been identified. Using functional genetic methods and mass spectrometry analysis, we have identified a phosphorylated serine residue in the FLI1 domain of EWS-FLI1 that regulates the stability of the EWS-FLI1 oncoprotein. Loss of phosphorylation of this serine residue triggers ubiquitination and proteasomal degradation of EWS-FLI1, and apoptotic cell death. Xenograft studies suggest this post-translational modification of EWS-FLI1 can be targeted in vivo and that this inhibits ES tumor growth. Citation Format: Nirmalya Sen, Katelyn Ludwig, Guillermo O. Rangel-Rivera, Suntae Kim, Konrad Huppi, Lisa Jenkins, Jennifer E. Dwyer, Shelley Hoover, Lee Helman, Mark Simpson, Arnulfo Mendoza, Amanda B. Hummon, Natasha J. Caplen. Targeting the expression of EWS-FLI1 [abstract]. In: Proceedings of the AACR Conference on Advances in Sarcomas: From Basic Science to Clinical Translation; May 16-19, 2017; Philadelphia, PA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(2_Suppl):Abstract nr IA04.
Malondialdehyde–Acetaldehyde Adducts and Antibody Responses in Rheumatoid Arthritis–Associated Interstitial Lung Disease
Authors: Bryant R. England, Michael J. Duryee, Punyasha Roul, Tina D. Mahajan, Namrata Singh, Jill A. Poole, Dana P. Ascherman, Liron Caplan, M. Kristen Demoruelle, Kevin D. Deane, Lynell W. Klassen, Geoffrey M. Thiele, Ted R. Mikuls
Journal: Arthritis & Rheumatology (2019)

Objective To compare serum anti–malondialdehyde–acetaldehyde (anti‐ MAA ) antibody levels and MAA expression in lung tissue from patients with rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) to those found in controls. Methods Anti‐ MAA antibody (IgA, IgM, IgG) concentrations were measured in patients with RA‐ILD and compared to those of RA patients with chronic obstructive pulmonary disease ( COPD ) and RA patients without lung disease. Associations between anti‐ MAA antibody with RA‐ILD were assessed using multivariable logistic regression. Lung tissue from patients with RA‐ILD , other ILD , or emphysema, and from controls (n = 3 per group) were stained for MAA , citrulline, macrophages ( CD 68), T cells ( CD 3), B cells ( CD 19/ CD 27), and extracellular matrix proteins (type II collagen, fibronectin, vimentin). Tissue expression and colocalization with MAA were quantified and compared. Results Among 1,823 RA patients, 90 had prevalent RA‐ILD . Serum IgA and IgM anti‐ MAA antibody concentrations were higher in RA‐ILD than in RA with COPD or RA alone ( P = 0.005). After adjustment for covariates, the highest quartiles of IgA anti‐ MAA antibody concentration (odds ratio 2.09 [95% confidence interval 1.11–3.90]) and IgM (odds ratio 2.23 [95% confidence interval 1.19–4.15]) were significantly associated with the presence of RA‐ILD. MAA expression in RA‐ILD lung tissue was greater than in tissue from all other groups ( P &lt; 0.001), and it colocalized with citrulline (r = 0.79), CD 19+ B cells (r = 0.78), and extracellular matrix proteins (type II collagen [r = 0.72] and vimentin [r = 0.77]) to the greatest degree in RA‐ILD . Conclusion Serum IgA and IgM anti‐ MAA antibody is associated with ILD among RA patients. MAA is highly expressed in RA‐ILD lung tissue, where it colocalizes with other RA autoantigens, autoreactive B cells, and extracellular matrix proteins, highlighting its potential role in the pathogenesis of RA‐ILD .